Analysts await Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.38 EPS, up 105.26% or $0.4 from last year’s $-0.78 per share.

At the moment 5 analysts are watching Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP), 3 rate it “Buy”, 1 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 0.00 million whilst for the year ending Dec-16, 5 analysts have a mean target of 0.00 million.

In terms of earnings per share, 1 analyst has a -0.40 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 1 analyst has a -0.46 EPS mean target and for the quarter ending Jun-16 there are 5 estimates of -1.73 EPS.

The biggest institutional shareholders in Aquinox Pharmaceuticals, Inc. include Baker Bros Advisors Llc which owns 7 million shares in the company valued at $86.74 million. RA Capital Management, LLC is the second biggest holder with 2 million shares currently valued at 20.22 million whilst Johnson has 2 million shares valued at 15.74 million.

Total shares held by institutions as of the most recent company filings are 22,298,599 with a reported 1,982,945 bought and 1,030,529 sold. These holdings make up 74.91% of the company’s outstanding shares.

Currently insiders hold 73,530 shares in the business which makes up 0.43% of shares. The biggest holder currently is Mr. David J. Main who owns 71,530 shares (0.42% of those outstanding), whilst Mr. David Chilton Mitchell holds 1,600 (0.0093% of shares outstanding) and Dr. Stephen B. Shrewsbury,M.B.,Ch.B. holds 400 (0.0023% of shares outstanding).

The stock increased 0.37% or $0.03 during the last trading session, hitting $19.50. Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has risen 9.85% over the past 6 months and is uptrending.